Results 121 to 130 of about 2,519,772 (150)

Role of Obeticholic Acid, a Farnesoid X Receptor Agonist, in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. [PDF]

touchREV Endocrinol
Kamrul-Hasan A, Mondal S, Nagendra L, Sasikanth T, Ahammed A, Rahman S, Wickramarachchi A, Parajuli N, Khatiwada S, Dutta D.   +9 more
europepmc   +1 more source

Obeticholic acid ameliorates sepsis-induced renal mitochondrial damage by inhibiting the NF-κb signaling pathway. [PDF]

Ren Fail
Jing D, Liu J, Qin D, Lin J, Li T, Li Y, Duan M.   +6 more
europepmc   +1 more source

The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Medicine (Baltimore)
Zhao J, Li B, Zhang K, Zhu Z.
europepmc   +1 more source

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. [PDF]

PLoS One
Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.   +4 more
europepmc   +1 more source

Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid. [PDF]

J Pharmacol Exp Ther
Meshanni JA, Lee JM, Vayas KN, Sun R, Jiang C, Guo GL, Gow AJ, Laskin JD, Laskin DL.   +8 more
europepmc   +1 more source

Obeticholic acid for primary biliary cholangitis. [PDF]

Aust Prescr, 2020
europepmc   +1 more source

Edaravone and obeticholic acid protect against cisplatin-induced heart toxicity by suppressing oxidative stress and inflammation and modulating Nrf2, TLR4/p38MAPK, and JAK1/STAT3/NF-κB signals. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
El-Shoura EAM, Hassanein EHM, Taha HH, Shalkami AS, Hassanein MMH, Ali FEM, Bakr AG.   +6 more
europepmc   +1 more source